Journal of Renal Nutrition
Volume 20, Issue 5 , Pages 321-328 , September 2010

Effects of Omega-3 Polyunsaturated Fatty-Acid Supplementation on Redox Status in Chronic Renal Failure Patients With Dyslipidemia

  • Nassima Bouzidi, MD

      Affiliations

    • Laboratoire de Nutrition Clinique et Métabolique, Département de Biologie, Faculté des Sciences, Université d'Oran, Es-Sénia, Oran, Algeria
    • ,
  • Khedidja Mekki, PhD

      Affiliations

    • Laboratoire de Nutrition Clinique et Métabolique, Département de Biologie, Faculté des Sciences, Université d'Oran, Es-Sénia, Oran, Algeria
    • Corresponding Author InformationAddress reprint requests to Khedidja Mekki, PhD, Laboratoire de Nutrition Clinique et Métabolique, Département de Biologie, Faculté des Sciences, Université d'Oran, Es-Sénia, Oran 31100, Algeria.
    • ,
  • Ali Boukaddoum, MD

      Affiliations

    • Laboratoire de Nutrition Clinique et Métabolique, Département de Biologie, Faculté des Sciences, Université d'Oran, Es-Sénia, Oran, Algeria
    • ,
  • Nawel Dida, MD

      Affiliations

    • Laboratoire de Nutrition Clinique et Métabolique, Département de Biologie, Faculté des Sciences, Université d'Oran, Es-Sénia, Oran, Algeria
    • ,
  • Abbou Kaddous, PhD

      Affiliations

    • Service de Néphrologie, Etablissement Hospitalo-Universitaire d'Oran, Oran, Algeria
    • ,
  • Malika Bouchenak, PhD

      Affiliations

    • Laboratoire de Nutrition Clinique et Métabolique, Département de Biologie, Faculté des Sciences, Université d'Oran, Es-Sénia, Oran, Algeria

References 

  1. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384
  2. Vaziri ND. Dyslipidemia of chronic renal failure. The nature, mechanisms, and potential consequences. Am J Physiol Ren Physiol. 2006;290:F262–F272
  3. Chan DT, Irish AB, Dogra CK, Watts GF. Dyslipidaemia and cardiorenal disease: Mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis. 2008;196:823–834
  4. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: An approach to pathogenesis and treatment. Am J Nephrol. 2008;28:958–973
  5. Prinsen BH, De Sain-van der Velden MG, De Koning EJ, Koomans HA, Berger R. Rabelink TJ: Hypertriglyceridemia in patients with chronic renal failure: Possible mechanisms. Kidney Int. 2003;63:121–124
  6. Mekki K, Bouchenak M, Remaoun M, Belleville J. Effect of long-term hemodialysis on plasma lecithin: Cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: A 9-year longitudinal study. Med Sci Monit. 2004;10:439–446
  7. Annuk M, Zilmer M, Fellstro B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int. 2003;63(Suppl):S50–S53
  8. Sies H. Oxidative stress: Oxidants and antioxidants. Exp Physiol. 1997;82:291–295
  9. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 3rd ed.. Oxford: Oxford University Press; 1999;140-163, 393-430
  10. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272–1280
  11. Lucchi L, Bergamini S, Iannone A, et al. Erythrocyte susceptibility to oxidative stress in chronic renal failure patients under different substitutive treatments. Treat Artif Organs. 2005;29:67–72
  12. Rutkowski B, Szolkiewicz M, Korczyńska J, et al. Interrelationship between uremic toxicity and oxidative stress. J Ren Nutr. 2006;16:190–193
  13. Ramos T, Martinez-Castelao A. Lipoperoxidation and hemodialysis. Metabolism. 2008;57:1369–1374
  14. Suresh DR, Delphine S, Agarwàl R. Biochemical markers of oxidative stress in predialytic chronic renal failure patients. Hong Kong J Nephrol. 2008;10:69–73
  15. Kandasamy N, Joseph F, Goenka N. The role of omega-3 fatty acids in cardiovascular disease, hypertriglyceridaemia and diabetes mellitus. Br J Diabetes Vasc Dis. 2008;8:121
  16. Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83:324–332
  17. Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol. 2006;1:182–192
  18. Trollfors B, Alestig K, Jagenburg R. Prediction of glomerular filtration rate from serum creatinine, age, sex and body weight. Acta Med Scand. 1987;221:495–508
  19. Quintanilha AT, Packer L, Davies JM, Racanelli TL, Davies KJ. Membrane effects of vitamin E deficiency: Bioenergetic and surface charge density studies of skeletal muscle and liver mitochondria. Ann NY Acad Sci. 1982;393:32–47
  20. Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464–478
  21. Aebi H, Catalase . In:  Berg Meyer H editors. Methods of enzymatic analysis. 2nd ed. Weinheim: Verlag Chemie; 1974;p. 673–684
  22. Holm T, Andreassen AK, Aukrust P, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J. 2001;22:428–436
  23. Fiedler R, Mall M, Wand C, et al. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr. 2005;15:253–256
  24. Dionisio P, Caramello E, Bergia R, et al. Atherogenic risk in patients undergoing regular dialysis treatment: Improvement of lipid pattern and lipoproteins by polyunsaturated omega-3 fatty acids. Nephrol Dial Transplant. 1994;9:458
  25. Schmitz PG, McCloud LK, Reikes ST, et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: Double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002;13:184–190
  26. Harris WS. Omega-3 long-chain PUFA and triglyceride lowering: Minimum effective intakes. Eur Heart J. 2002;3(Suppl 3):D59–D61
  27. Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6:391–409
  28. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA. 2006;296:1885–1899
  29. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–1903
  30. Miyata T, Kurokawa K. van Ypersele de Strihou C: Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int. 2000;76(Suppl):S120–S125
  31. Shidfar F, Keshavarz A, Hosseyni S, et al. Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes patients. East Mediterran Health J. 2008;14:305–315
  32. Romieu I, Garcia-Esteban R, Sunyer J, et al. The effect of supplementation with omega-3 polyunsaturated fatty acids on markers of oxidative stress in elderly exposed to PM2.5. Environ Health Perspect. 2008;116:1237–1242
  33. Nenseter MS, Drevon CA. Dietary polyunsaturates and peroxidation of low density lipoproteins. Curr Opin Lipidol. 1996;7:8–13
  34. Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol. 2003;17:24–38
  35. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;833(Suppl):1505S–1519S
  36. Valko M, Rhodes CJ, Moncol J, et al. Free radicals, metals and antioxidants in oxidative stress induced cancer. Chem Biol Interact. 2006;160:1–40
  37. Rahman Adcock. IM: Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28:219–242
  38. Zararsiz I, Sonmez MF, Yilmaz HR, et al. Effects of omega-3 essential fatty acids against formaldehyde-induced nephropathy in rats. Toxicol Ind Health. 2006;22:223–229
  39. Arab K, Rossary A, Flourie F, et al. Docosahexaenoic acid enhances the antioxidant response of human fibroblasts by upregulating gammaglutamyl-cysteinyl ligase and glutathione reductase. Br J Nutr. 2006;95:18–22

PII: S1051-2276(10)00003-8

doi: 10.1053/j.jrn.2010.01.002

Journal of Renal Nutrition
Volume 20, Issue 5 , Pages 321-328 , September 2010

Article Tools